Your Health, We Care

Home > Photo Wall > Honor and qualification

Production approval for Sotorasib

Release date: 2024-07-10 11:18:27     Recommended: 154

04L0960_23 AMG-510 批文_00.jpg

Sotiracib is used in FDA approved trials to identify lung disease patients with KRAS G12C mutations who have received at least one systemic treatment. By forming irreversible covalent bonds with the unique cysteine of KRAS G12C, the protein is locked in an inactive state, thereby blocking downstream signaling, inhibiting cell growth, and promoting apoptosis, playing a therapeutic role in the disease.

Company News

Research News

Drug news